

## CURRICULUM VITAE

### VITAL STATISTICS:

Name	Carlo Patrono
Date of birth	September 1, 1944
Citizenship	Italy
Marital status	Married: Angelamaria Zampini
	Children: Vito Matteo 17/5/73
	Livia Victoria 3/6/86

### EDUCATION:

1962	B.S	Arts	Liceo Classico Nazareno; Rome, Italy
1968	M.D.	Cum Laude	Catholic University School of Medicine (UCSC), Rome, Italy
1969-1971	Research Fellow	Medicine	Bronx Veterans Administration Hospital and Mount Sinai School of Medicine, New York, USA

### PROFESSIONAL EXPERIENCE:

1972-1982	Assistant Professor of Pharmacology	Department of Pharmacology, UCSC, Rome
1983-1990	Associate Professor of Pharmacology	Department of Pharmacology UCSC, Rome
1984-1985	Lecturer in Medicine	Mount Sinai School of Medicine, New York, USA
1985-1986	Visiting Professor	Department of Pharmacology, King's College, London, Departments of Medicine (Cardiovascular Unit) and Clinical Pharmacology, Royal Postgraduate Medical School London, UK
1991-2001	Professor of Pharmacology	“G. D'Annunzio” University of Chieti School of Medicine
1996-1997	Visiting Professor of Pharmacology	University of Pennsylvania School of Medicine, Philadelphia, USA
2001-	Scientific Director, MIUR Center	“G. D'Annunzio” University of Chieti

of Excellence on Aging

2001-2006	Professor of Pharmacology	“La Sapienza” University of Rome, 2 <sup>nd</sup> School of Medicine
2007-2014	Professor and Chair of Pharmacology	UCSC, Rome
2015-	Adjunct Professor of Pharmacology	UCSC, Rome
2015-2022	Adjunct Professor of Pharmacology	University of Pennsylvania Perelman School of Medicine, Philadelphia, USA

**PROFESSIONAL & SCIENTIFIC MEMBERSHIPS:**

- Member of the Italian Society of Pharmacology, 1968-
- Honorary Member of the Association of American Physicians, 1991-
- Fellow of the European Society of Cardiology, 1994-
- Member of the Council on Thrombosis of the International Society and Federation of Cardiology, 1994-1996
- Chairman, Working Group "Thrombosis and Platelets" of the European Society of Cardiology, 1994-1996
- Fellow of the Royal College of Physicians in Ireland, 1998-
- Chairman, Task Force on Antithrombotic Agents of the European Society of Cardiology, 2000-2003, 2009-2011 and 2016-2017
- External Advisor, NIH Center in Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, 2000-2004
- Fellow of the Royal College of Physicians, 2003-
- Member of Academia Europaea, 2004-
- Member of Accademia Nazionale dei Lincei, 2004-
- Honorary Member of Académie Royale de Médecine de Belgique, 2011-
- Member of the International Scientific Advisory Committee of the Dutch Heart Foundation, 2012-19
- Co-Chairman, Task Force NSTEMI-ACS Guidelines of the European Society of Cardiology, 2013-15
- Member of the SAPEA Working Group “Transforming the Future of Ageing”, 2018-19
- Member (2013-2022) and Chairman (2017-2022) of the Scientific Advisory Board, and Honorary Fellow (2023-) of the International Aspirin Foundation

- Member of the Scientific Advisory Board of the William Harvey Research Institute, 2012-

#### **AWARDS and HONORS:**

1980: Alexander B. Gutman Visiting Professorship of Medicine, awarded by the Mount Sinai School of Medicine, New York

1981: Upjohn Award "Excellence in Pharmacology" of the Italian Society of Pharmacology

1982: W.N. Creasy Visiting Professorship of Clinical Pharmacology, awarded by the Burroughs Wellcome Fund

1985: Senior Fellowship, awarded by the British Council

1998: International Aspirin® Senior Award, awarded by Bayer AG

2007: John Vane Award from the William Harvey Research Institute of the University of London

2011: Outstanding Achievement Award of the Eicosanoid Research Foundation

2013: Grand Prix Scientifique de la Fondation Lefoulon-Delalande, awarded by Institut de France

2013: Lifetime Achievement Award of the European Association for Clinical Pharmacology and Therapeutics

2021: Gaddum International Lectureship awarded by the British Pharmacological Society

#### **EDITORIAL ACTIVITIES:**

**Co-Editor** of 7 books and journal issues (see list of publications).

Member of the Editorial Board of **Clinical and Experimental Rheumatology** (1982-present)

Member of the Editorial Board of the **European Journal of Clinical Pharmacology** (1984-2007)

Member of the Editorial Board of **Trends in Cardiovascular Medicine** (1990-1995)

Member of the Editorial Board of **Pharmacological Research** (1999-present)

Member of the Editorial Advisory Board of **Molecular Interventions**, (2005-2011)

Member of the Editorial Board of **Circulation** (2000-2016)

Member of the Editorial Board of **Arteriosclerosis, Thrombosis and Vascular Biology** (2002-2016)

Section Editor for the area of Pharmacology, **Journal of the American College of Cardiology** (2014-)

Associate Editor of the **International Journal of Cardiology** (2016-2020)

Deputy Editor of the **European Heart Journal** (2020-)

## **FUNDED RESEARCH PROJECTS 2015-2025:**

1. Medical Research Council and Cancer Research UK "Add-Aspirin Trial" (2015-2025): Member of the Steering Committee
2. Italian Drug Agency (AIFA) "Novel strategies of antithrombotic prophylaxis in patients with essential thrombocythemia at high risk of cardiovascular events: comparison of different dosing regimens of administration of low-dose acetylsalicylic acid" (2016-2020): Study Chairman
3. Cancer Research UK, "Aspirin for Cancer Prevention Collaboration" Catalyst Grant (2018-2023): Co-Investigator
4. Bayer "Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetic patients with stable peripheral or carotid artery disease: a randomized, crossover study" (2019-2020): Scientific Coordinator.

## **PEER REVIEW:**

Ad-hoc reviewer of grant applications for the following Organizations:

- Swiss International Science Foundation
- Swedish Research Council
- British Heart Foundation
- Canadian Council for the Arts, Killam Program
- INSERM
- Dutch Heart Foundation

## **PUBLICATIONS:**

Books and Journal Issues	7
Original Articles, Reviews and Editorials	244
Chapters in Books and Congress Proceedings	126
Short Commentaries	72
Total citations (Source: Google Scholar)	>85,000
<i>h</i> -index (Source: Google Scholar)	113

**ORIGINAL ARTICLES, REVIEWS AND EDITORIALS  
IN PEER-REVIEWED JOURNALS**

- 1) Serra A, Sargentini S, Patrono C, Ferrara A, Laghi V. 45, X, G- , Ph1 cell line in bone marrow and blood of CML affected male. **Ann Genet**, 13:239-243, 1970.
- 2) Patrono C. Radioimmunoassay of Prostaglandin F<sub>2α</sub> in unextracted human plasma. **J Nucl Biol Med**, 17:25-29, 1973.
- 3) Pozzuoli R, Musiani P, Arru E, Patrono C, Piantelli M. Echinococcus granulosus: evaluation of purified antigens immunoreactivity. **Exp Parasitol**, 35:52-60, 1974.
- 4) La Torre E, Patrono C, Fortuna A, Grossi-Belloni D. Role of Prostaglandin F<sub>2α</sub> in human cerebral vasospasm. **J Neurosurg**, 41:293-299, 1974.
- 5) Patrono C, Ciabattoni G, Grossi-Belloni D. *In vitro* and *in vivo* inhibition of Prostaglandin synthesis by Fenoprofen, a non steroid anti-inflammatory drug. **Pharmacol Res Commun**, 6:509-518, 1974.
- 6) Patrono C, Grossi-Belloni D, Ciabattoni G, Serra GB, La Torre E, Bombardieri S, Mancuso S, Gorga C. Radioimmunoassay measurement of F Prostaglandins in human body fluids. **Horm Metab Res Supplement series 5**:190-195, 1974.
- 7) Greco AV, Ghirlanda G, Patrono C, Fedeli G, Manna R. Behaviour of pancreatic glucagon, insulin and HGH in liver cirrhosis, after arginine and i.v. glucose. **Acta Diabetol Lat**, 11:330-339, 1974.
- 8) Patrono C, Ciabattoni G, Grossi-Belloni D. Release of Prostaglandin F<sub>1α</sub> and F<sub>2α</sub> from superfused platelets: quantitative evaluation of the inhibitory effects of some Aspirin-like drugs. **Prostaglandins**, 9:557-568, 1975.
- 9) Togna G, Gandolfi C, Andreoni A, Fumagalli A, Passarotti C, Faustini F, Patrono C. Inhibition of human platelet aggregation by stable analogs of prostacyclin. **Pharmacol Res Commun**, 9:909-916, 1977.
- 10) Patrono C, Ciabattoni G, Venuti A, Pugliese F, Schiavino D, Patriarca G. Aspirin intolerance: unaltered susceptibility of platelet cyclooxygenase to inhibition by aspirin in vitro. **J Allergy Clin Immunol**, 62:271-275, 1978.
- 11) Ciabattoni G, Pugliese F, Spaldi M, Cinotti GA, Patrono C. Radioimmunoassay measurement of prostaglandins E<sub>2</sub> and F<sub>2α</sub> in human urine. **J Endocrinol Invest**, 2:173-182, 1979.
- 12) Ciabattoni G, Pugliese F, Cinotti GA, Stirati G, Ronci R, Castrucci G, Pierucci A, Patrono C. Characterization of furosemide-induced activation of the renal prostaglandin system. **European J Pharmacol**, 60:181-187, 1979.
- 13) Patrono C, Wennmalm A, Ciabattoni G, Nowak J, Pugliese F, Cinotti GA. Evidence for an extra-renal origin of urinary prostaglandin E<sub>2</sub> in healthy men. **Prostaglandins**, 18:623-629, 1979.
- 14) Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low-dose aspirin and inhibition of thromboxane B<sub>2</sub> production in healthy subjects. **Thromb Res**, 17:317-327, 1980.

- 15) Patrono C, Pugliese F. The involvement of arachidonic acid metabolism in the control of renin release. **J Endocrinol Invest**, 3:193-201, 1980.
- 16) Caruso I, Moro E, Patrono C, Sacchetti G, Tamassia V, Tosolini GP. Plasma and synovial fluid pharmacokinetics and prostaglandin inhibitory effect of indoprofen in patients with rheumatoid arthritis. **Scand J Rheumatol**, 9:123-126, 1980.
- 17) Patrono C, Pugliese F, Ciabattoni G, Di Blasi S, Pierucci A, Cinotti GA, Maseri A, Chierchia S. Prostacyclin does not affect insulin secretion in humans. **Prostaglandins**, 21:379-385, 1981.
- 18) Bombardieri S, Cattani P, Ciabattoni G, Di Munno O, Pasero GP, Patrono C, Pinca E, Pugliese F. The synovial prostaglandin system in chronic inflammatory arthritis. Differential effects of steroidal and nonsteroidal antiinflammatory drugs. **Br J Pharmacol**, 73:893-901, 1981.
- 19) Patrono C, Rotella CM, Toccafondi R, Aterini S, Pinca E, Tanini A, Zonefrati R. Prostacyclin stimulates the adenylate cyclase system of human thyroid tissue. **Prostaglandins**, 22:105-115, 1981.
- 20) Edlund A, Bomfin W, Kaijser L, Olin C, Patrono C, Pinca E, Wennmalm A. Pulmonary formation of prostacyclin in man. **Prostaglandins**, 22:323-332, 1981.
- 21) Chierchia S, Patrono C, Crea F, Ciabattoni G, De Caterina R, Cinotti GA, Distante A, Maseri A. Effects of intravenous prostacyclin in variant angina. **Circulation**, 65:470-477, 1982.
- 22) Patrono C, Pugliese F, Ciabattoni G, Patrignani P, Maseri A, Chierchia S, Cinotti GA, Simonetti BM, Pierucci A, Peskar BA. Evidence for a direct stimulatory effect of prostacyclin on renin release in man. **J Clin Invest**, 69:231-239, 1982.
- 23) Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. **J Clin Invest**, 69:1366-1372, 1982.
- 24) Chierchia S, De Caterina R, Crea F, Patrono C, Maseri A. Failure of thromboxane A2 blockade to prevent attacks of vasospastic angina. **Circulation**, 66:702-705, 1982.
- 25) Edlund A, Bomfin W, Kaijser L, Olin C, Patrono C, Pinca E, Wennmalm A. Cardiac formation of prostacyclin during cardioplegia in man. **Prostaglandins**, 24:5-19, 1982.
- 26) Aehringhaus U, Wolbing RH, Konig W, Patrono C, Peskar BM, Peskar BA. Release of Leukotriene C<sub>4</sub> from human polymorphonuclear leucocytes as determined by radioimmunoassay. **FEBS letters**, 146:111-114, 1982.
- 27) Eriksson S, Hagenfeldt L, Law D, Patrono C, Pinca E, Wennmalm A. Effect of prostaglandin synthesis inhibitors on basal and carbon dioxide stimulated cerebral blood flow in man. **Acta Physiol Scand**, 117:203-211, 1983.
- 28) Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, De Gaetano G, Day JS, Smith WL, Pinca E, Patrignani P, Patrono C. Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. **J Clin Invest**, 71:762-768, 1983.
- 29) FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. **Circulation**, 67:1174-1177, 1983.

- 30) Edlund A, Fredholm BB, Patrignani P, Patrono C, Wennmalm A, Wennmalm M. Release of two vasodilators -adenosine and prostacyclin- from isolated rabbit hearts during controlled hypoxia. **J Physiol (Lond)**, 340:487-501, 1983.
- 31) Patrignani P, Filabozzi P, Catella F, Pugliese F, Patrono C. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin endoperoxide metabolism. **J Pharmacol Exp Ther**, 228:472-477, 1984.
- 32) Ciabattoni G, Cinotti GA, Pieurucci A, Simonetti BM, Manzi M, Pugliese F, Barsotti P, Pecci G, Taggi F, Patrono C. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. **N Engl J Med**, 310:279-283, 1984.
- 33) Patrono C, Preston FE, Vermylen J. Platelet and vascular arachidonic acid metabolites. Can they help detect a tendency towards thrombosis? **Br J Haematol**, 57:209-212, 1984.
- 34) Patrono C. Tissue-selective inhibition of prostaglandin and thromboxane synthesis in man: investigative and therapeutic implications. **Clin Physiol**, 4:443-447, 1984.
- 35) Lindgren JA, Hokfelt T, Dahlen S-E, Patrono C, Samuelsson B. Leukotrienes in the rat central nervous system. **Proc Natl Acad Sci USA**, 81:6212-6216, 1984.
- 36) Hulting A-L, Lindgren J-A, Hokfelt T, Heidvall K, Eneroth P, Werner S, Patrono C, Samuelsson B. Leukotriene C<sub>4</sub> stimulates LH secretion from rat pituitary cells *in vitro*. **Eur J Pharmacol**, 106:459-460, 1984.
- 37) De Caterina R, Giannessi D, Bernini W, Gazzetti P, Michelassi C, L'Abbate A, Donato L, Patrignani P, Filabozzi P, Patrono C. Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. **Am J Cardiol**, 55:589-590, 1985.
- 38) Patrono C, Ciabattoni G, Patrignani P, Filabozzi P, Catella F, Davi G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. **Circulation**, 72: 1177-1184, 1985.
- 39) Alessandrini P, Avogaro P, Bittolo Bon G, Patrignani P, Patrono C. Physiologic variables affecting thromboxane B<sub>2</sub> production in human whole blood. **Thromb Res**, 37:1-8, 1985.
- 40) Hulting AL, Lindgren JA, Hokfelt T, Eneroth P, Werner S, Patrono C, Samuelsson B. Leukotrienes C<sub>4</sub> as a mediator of luteinizing hormone release from rat anterior pituitary cells. **Proc Natl Acad Sci USA**, 82:3834-3838, 1985.
- 41) Edlund A, Berglund B, Van Dorne D, Kaijser L, Nowak J, Patrono C, Sollevi A, Wennmalm A. Coronary flow regulation in patients with ischemic heart disease: release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation. **Circulation**, 71:1113-1120, 1985.
- 42) De Caterina R, Giannessi D, Bernini W, Gazzetti P, Michelassi C, L'Abbate A, Donato L, Patrignani P, Filabozzi P, Patrono C. Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. **Eur Heart J**, 6:409-417, 1985.

- 43) De Caterina R, Giannessi D, Boem A, Bernini W, Battaglia D, Michelassi C, Dell'Amico F, L'Abbate A, Patrignani P, Patrono C. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. **Thromb Haemostas**, 54:528-532, 1985.
- 44) Patrono C, Ciabattoni G, Remuzzi G, Gotti E, Bombardieri S, Di Munno O, Tartarelli G, Cinotti GA, Simonetti BM, Pierucci A. Functional significance of renal prostacyclin and thromboxane A<sub>2</sub> production in patients with Systemic Lupus Erythematosus. **J Clin Invest**, 76:1011-1018, 1985.
- 45) Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal man. **J Clin Invest**, 77:590-594, 1986.
- 46) Lawson JA, Patrono C, Ciabattoni G, FitzGerald GA. Long lived enzymatic metabolites of thromboxane B<sub>2</sub> in the human circulation. **Anal Biochem**, 155:198-205, 1986.
- 47) Patrono C. Aspirin for the prevention of coronary thrombosis: current facts and perspectives. **Eur Heart J**, 7:454-459, 1986.
- 48) Patrono C, Pierucci A. Renal effects of nonsteroidal antiinflammatory drugs in chronic glomerular disease. **Am J Med**, 81:71-83, 1986.
- 49) Bertani T, Livio M, Macconi D, Morigi M, Bisogno G, Patrono C, Remuzzi G. Platelet-activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. **Kidney Int**, 31:1248-1256, 1987.
- 50) Ciabattoni G, Boss AH, Patrignani P, Catella F, Simonetti BM, Pierucci A, Pugliese F, Filabozzi P, Patrono C. Effects of sulindac on renal and extrarenal eicosanoid synthesis. **Clin Pharmacol Ther**, 41:380-383, 1987.
- 51) Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. **Kidney Int**, 32:1-12, 1987.
- 52) Ciabattoni G, Maclouf J, Catella F, FitzGerlad GA, Patrono C. Radioimmunoassay of 11-dehydro-thromboxane B<sub>2</sub> in human plasma and urine. **Biochim Biophys Acta**, 918:293-297, 1987.
- 53) Chierchia S, Patrono C. The role of platelet and vascular eicosanoids in the pathophysiology of ischaemic disease. **Fed Proc**, 46:81-88, 1987.
- 54) Pierucci A, Simonetti BM, Pecci G, Mavrikakis G, Feriozzi S, Cinotti GA, Patrignani P, Ciabattoni G, Patrono C. Improvement of renal function with selective thromboxane antagonism in lupus nephritis. **N Engl J Med**, 320:421-425, 1989.
- 55) Ciabattoni G, Pugliese F, Davi G, Pierucci A, Simonetti BM, Patrono C. Fractional conversion of thromboxane B<sub>2</sub> to urinary 11-dehydro-thromboxane B<sub>2</sub> in man. **Biochim Biophys Acta**, 992:66-70, 1989.
- 56) Patrignani P, Morton H, Cirino M, Lord A, Charette L, Gillard J, Rokach J, Patrono C. Fractional conversion of thromboxane A<sub>2</sub> and B<sub>2</sub> to urinary 2,3-dinor-thromboxane B<sub>2</sub> and 11-dehydro-thromboxane B<sub>2</sub> in the cynomolgus monkey. **Biochim Biophys Acta**, 992:71-77, 1989.
- 57) Macconi D, Benigni A, Morigi M, Ubiali A, Orisio S, Livio M, Perico N, Bertani T, Remuzzi G, Patrono C. Enhanced glomerular thromboxane A<sub>2</sub> mediates some pathophysiologic effects of platelet-



activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials. **J Lab Clin Med**, 113:594-560, 1989.

58) Benigni A, Chiabrando C, Perico N, Fanelli R, Patrono C, Fitzgerald G, Remuzzi G. Renal metabolism and urinary excretion of thromboxane B<sub>2</sub> in the rat. **Am J Physiol**, 257:F77-85, 1989.

59) Nicosia S, Patrono C. Eicosanoid biosynthesis and action: novel opportunities for pharmacologic intervention. **FASEB J**, 3:1941-1948, 1989.

60) Patrono C. Measurement of thromboxane biosynthesis in man. **Eicosanoids**, 2:249-251, 1989.

61) Ferrario RG, Foukles R, Salvati P, Patrono C. Hemodynamic and tubular effects of endothelin and thromboxane in the isolated perfused rat kidney. **Eur J Pharmacol**, 171:127-134, 1989.

62) Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. **Trends Pharmacol Sci**, 10:453-458, 1989.

63) Vejar M, Fragasso G, Hackett D, Lipkin PD, Maseri A, Born GVR, Ciabattini G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. **Thromb Haemost**, 63:163-168, 1990.

64) Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattini G, Patrono C. Thromboxane biosynthesis and platelet function in type-II diabetes mellitus. **N Engl J Med**, 322:1769-1774, 1990.

65) Salvati P, Ferti C, Ferrario RG, Lamberti E, Duzzi L, Bianchi G, Remuzzi G, Perico N, Benigni A, Braidotti P, Coggi G, Pugliese F, Patrono C. Role of enhanced glomerular synthesis of thromboxane A<sub>2</sub> in progressive kidney disease. **Kidney Int**, 38:447-452, 1990.

66) De Caterina R, Boem A, Gazzetti P, Sicari R, Giannessi D, Ciabattini G, Patrono C. Long-term maintenance of thromboxane inhibition by two different aspirin regimens in patients with unstable angina. **Thromb Res**, 60:169-175, 1990.

67) Patrignani P, Volpi D, Ferrario R, Romanzini L, Patrono C. Effects of racemic-, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood. **Eur J Pharmacol**, 191:83-88, 1990.

68) Salvati P, Dho L, Ferrario RG, Parenti P, Vicedomini G, Chierchia S, Patrono C. Proarrhythmic activity of intracoronary endothelin in the dog: relation to the site of administration and to changes in regional flow. **J Cardiovasc Pharmacol**, 17:1007-1014, 1991.

69) Fabbrini MS, Vitale A, Patrono C, Zamai M, Vaghi F, Caiolfa V, Monaco L, Benatti L. Heterologous *in vivo* processing of human preproendothelin-1 into bioactive peptides. **Proc Natl Acad Sci USA**, 88:8939-8943, 1991.

70) Patrignani P, Del Maschio A, Bazzoni G, Hernandez A, Modica R, Montesanti L, Volpi D, Patrono C, Dejana E. Inactivation of Endothelin by polymorphonuclear leukocytes-derived lytic enzymes. **Blood**, 78:2715-2720, 1991.

71) Tarugi P, Nicolini S, Albertazzi L, Calandra S, Salvati P, Ferti C, Patrono C. Dyslipoproteinemia in an inbred rat strain with spontaneous chronic progressive nephrotic syndrome. **J Lipid Res**, 32:1675-1687, 1991.

- 72) Remuzzi G, FitzGerald GA, Patrono C. Thromboxane synthesis and action within the kidney. **Kidney Int**, 41:1483-1493, 1992.
- 73) Davì G, Notarbartolo A, Catalano I, Averna M, Barbagallo C, Ciabattoni G, Patrono C. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. **Circulation**, 85:1792-1798, 1992.
- 74) Maclouf J, Antoine C, De Caterina R, Sicari R, Murphy RC, Patrignani P, Loizzo S, Patrono C. Entry rate and metabolism of leukotriene C<sub>4</sub> into the vascular compartment in healthy subjects. **Am J Physiol**, 263:H-244-249, 1992.
- 75) Landolfi R, Ciabattoni G, Patrignani P, Castellana MAL, Pogliani E, Bizzi B, Patrono C. Increased thromboxane biosynthesis in patients with polycythemia vera. Evidence for aspirin-suppressable platelet activation *in vivo*. **Blood**, 80:1965-1971, 1992.
- 76) Salvati P, Dho L, Calabresi M, Rosa B, Patrono C. Evidence for a direct vasoconstrictor effect of Big Endothelin-1 in the rat kidney. **Eur J Pharmacol**, 221:267-273, 1992.
- 77) Zamai M, Menziani MC, De Benedetti PG, Patrono C, Caiolfa VR. Sequence-directed peptide inhibitor for human big Endothelin. **Med Chem Res**, 2:208-212, 1992.
- 78) Patrignani P, Daffonchio L, Hernandez A, De Caterina R, Pelosi G, Patrono C. Release of contracting autocoids by aortae of normal and atherosclerotic rabbits. **J Cardiovasc Pharmacol**, 20:S208, 1992.
- 79) Koudstaal PJ, Ciabattoni G, Van Gijn J, Nieuwenhuis HK, De Groot P, Sixma JJ, Patrono C. Increased thromboxane biosynthesis in patients with acute cerebral ischemia. **Stroke**, 24:219-223, 1993.
- 80) Ciabattoni G, Ujang S, Sritara P, Andreotti F, Davies G, Simonetti BM, Patrono C, Maseri A. Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterisation or coronary angioplasty. **J Am Coll Cardiol**, 21:1377-1381, 1993.
- 81) Fabbrini MS, Vitale A, Pedrazzini E, Nitti G, Zamai M, Tamburin M, Caiolfa VR, Patrono C, Benatti L. *In vivo* expression of mutant preproendothelins: hierarchy of processing events but no strict requirement of Trp-Val at the processing site. **Proc Natl Acad Sci USA**, 90:3923-3927, 1993.
- 82) Patrignani P, Modica R, Bertolero F, Patrono C. Differential effects of leukotriene C<sub>4</sub> on endothelin-1 and prostacyclin release by cultured vascular cells. **Pharmacol Res**, 27:281-285, 1993.
- 83) Créminon C, Frobert Y, Habib A, Maclouf J, Patrono C, Pradelles P, Grassi J. Enzyme immunometric assay for endothelin using tandem monoclonal antibodies. **J Immunol Methods**, 162:179-192, 1993.
- 84) De Ferrari GM, Salvati P, Grossoni M, Ukmar G, Vaga L, Patrono C, Schwartz PJ. Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. A study with propranolol, methacoline and oxotremorine in conscious dogs with a healed myocardial infarction. **J Am Coll Cardiol**, 21:283-290, 1993.
- 85) Di Minno G, Davì G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, Catalano I, Strisciuglio P, Andria G, Patrono C, Mancini M. Abnormally high thromboxane A<sub>2</sub> biosynthesis in homozygous

homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. **J Clin Invest**, 92:1400-1406, 1993.

86) Davì G, Patrono C, Catalano I, Custro N, Giammarresi C, Ganci A, Cosentino F, Notarbartolo A. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. **Arterioscler Thromb**, 13:1346-1349, 1993.

87) Patrono C, Davì G. Antiplatelet agents in the prevention of diabetic vascular complications. **Diabetes Metab Rev**, 9:177-188, 1993.

88) Van Kooten F, Ciabattoni G, Patrono C, Schmitz PIM, Van Gijn J, Koudstaal PJ. Evidence for episodic platelet activation in acute ischemic stroke. **Stroke**, 25:278-281, 1994.

89) Patrono C. Aspirin as an antiplatelet drug. **N Engl J Med**, 330: 1287-1294, 1994.

90) Salvati P, Dho L, Ukmar G, Vaga L, Rimoldi O, Patrono C. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis. **J Pharmacol Exp Ther**, 269: 238-245; 1994.

91) Landolfi R, De Candia E, Rocca B, Ciabattoni G, Antinori A, Masetti R, Patrono C. Effects of unfractionated and low molecular weight heparins on thromboxane biosynthesis "in vivo". **Thromb Haemost**, 72:942-946, 1994.

92) Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Créminon C, Maclouf J, Patrono C. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. **J Pharmacol Exp Ther**, 271:1705-1712, 1994.

93) Notarbartolo A, Davì G, Averna M, Barbagallo MB, Ganci A, Giammarresi C, La Placa FP, Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. **Arterioscler Thromb Vasc Biol**, 15:247-251, 1995.

94) Pugliese F, Ferrario RG, Ciavolella A, Tamburin M, Benatti L, Casini A, Patrono C, Salvati P. Growth abnormalities in cultured mesangial cells from rats with spontaneous glomerulosclerosis. **Kidney Int**, 47:106-113; 1995.

95) Salvati P, Lamberti E, Ferrario R, Ferrario RG, Scampini G, Pugliese F, Barsotti P, Patrono C. Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis. **Kidney Int**, 47:1168-1175, 1995.

96) Mené P, Pugliese F, Patrono C. The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. **Semin Nephrol**, 15:244-252, 1995.

97) Patrono C, Patrignani P, Rocca B, Landolfi R. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. **Thromb Haemost**, 74:396-400, 1995.

98) Barbui T, de Gaetano G, Finazzi G, Landolfi R, Marchioli R, Patrono C, Tognoni G and the Gruppo Italiano Studio Policitemia (GISP). Polycythemia Vera: the natural history of 1213 patients followed for 20 years. **Ann Intern Med**, 123:656-661, 1995.

- 99) Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. **Crit Rev Oncol Hematol**, 20:203-222, 1995.
- 100) Cipollone F, Ganci A, Panara MR, Greco A, Cuccurullo F, Patrono C, Patrignani P. Effects of nabumetone on prostanoid biosynthesis in man. **Clin Pharmacol Ther**, 58:335-341, 1995.
- 101) Wang Z, Ciabattoni G, Créminon C, Lawson J, FitzGerald GA, Patrono C, Maclouf J. Immunological characterization of urinary 8-epi-prostaglandin F<sub>2α</sub> excretion in man. **J Pharmacol Exp Ther**, 275:94-100, 1995.
- 102) Panara MR, Greco A, Santini G, Sciulli MG, Rotondo MT, Padovano R, Di Giamberardino M, Cipollone F, Cuccurullo F, Patrono C, Patrignani P. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-indanone (L-745,337), on the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases **Br J Pharmacol**, 116:2429-2434, 1995.
- 103) Rocca B, Ciabattoni G, Tartaglione R, Cortellazzo S, Barbui T, Patrono C, Landolfi R. Increased thromboxane biosynthesis in essential thrombocythemia. **Thromb Haemost**, 74:1225-1230, 1995.
- 104) Hirsh J, Dalen J, Fuster V, Harker L, Patrono C, Roth G. Aspirin and other platelet active drugs: the relationship among dose, effectiveness and side effects. **Chest**, 108:247S-257S, 1995.
- 105) Patrono C, Roth GJ. Aspirin in ischemic cerebrovascular disease: how strong is the case for a different dosing regimen? **Stroke**, 27:756-760, 1996.
- 106) Patrignani P, Santini G, Panara MR, Sciulli MG, Greco A, Rotondo MT, di Giamberardino M, Maclouf J, Ciabattoni G, Patrono C. Induction of prostaglandin endoperoxide synthase-2 in human monocytes is associated with cyclooxygenase-dependent F<sub>2</sub>-isoprostane formation. **Br J Pharmacol**, 118:1285-1293, 1996.
- 107) Landolfi R, Patrono C. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. **Leuk Lymphoma**, 22:83-86, 1996.
- 108) Patrono C. Unstable coronary artery disease: need for long-term antithrombotic treatment? **Cardiovasc Res**, 33:295-296, 1997.
- 109) Barbui T, de Gaetano G, Finazzi G, Landolfi R, Marchioli R, Patrono C, Tognoni G and Gruppo Italiano Studio Policitemia Vera (GISP). Low-dose aspirin in Polycythemia Vera: a pilot study. **Br J Haematol**, 97:453-456, 1997.
- 110) Davì G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, Patrono C. Diabetes mellitus, hypercholesterolemia and hypertension, but not vascular disease per se, are associated with persistent platelet activation *in vivo*. Evidence derived from the study of peripheral arterial disease. **Circulation**, 96:69-75, 1997.
- 111) Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. **Thromb Haemost**, 78:617-621, 1997.

- 112) Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. **Circulation**, 96:1109-1116, 1997.
- 113) Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. **Arterioscler Thromb Vasc Biol**, 17:2309-2315, 1997.
- 114) Davì G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bittolo Bon G, Ciabattoni G, Patrono C. In vivo formation of 8-epi-prostaglandin F<sub>2α</sub> is increased in hypercholesterolemia. **Arterioscler Thromb Vasc Biol**, 17:3230-3235, 1997.
- 115) van Kooten F, Ciabattoni G, Patrono C, Dippel DWJ, Koudstaal PJ. Platelet activation and lipid peroxidation in patients with acute ischemic stroke. **Stroke**, 28:1557-1563, 1997.
- 116) Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. **Thromb Haemostas**, 79:691-705, 1998.
- 117) Panara MR, Padovano R, Sciulli MG, Santini G, Renda G, Rotondo MT, Pace A, Patrono C, Patrignani P. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings. **Clin Pharmacol Ther**, 63:672-681, 1998.
- 118) Patrono C, Collier B, Dalen JE, Fuster V, Gent M, Harker LB, Hirsh J, Roth G. Platelet-Active Drugs: The relationships among dose, effectiveness, and side effects. **Chest**, 114:470S-488S, 1998.
- 119) Davì G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. *In vivo* formation of 8-iso-prostaglandin F<sub>2α</sub> and platelet activation in diabetes mellitus. Effects of improved metabolic control and vitamin E supplementation. **Circulation**, 99:224-229, 1999.
- 120) Van Kooten F, Ciabattoni G, Koudstaal PJ, Dippel DWJ, Patrono C. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. **Stroke**, 30:546-549, 1999.
- 121) Panara MR, Renda G, Sciulli MG, Santini G, Rotondo MT, Patrono C, Patrignani P. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. **J Pharmac Exp Ther**, 290:276-280, 1999.
- 122) Rocca B, Spain LM, Ciabattoni G, Patrono C, FitzGerald GA. Differential expression and regulation of cyclooxygenase isozymes in thymic stromal cells. **J Immunol**, 162:4589-4597, 1999.
- 123) Rocca B, Spain LM, Puré E, Langenbach R, Patrono C, FitzGerald GA. Distinct roles of prostaglandin H-synthases 1 and 2 in T-cell development. **J Clin Invest**, 103:1469-1477, 1999
- 124) Van Kooten F, Ciabattoni G, Koudstaal PJ, Grobbee DE, Kluft C, Patrono C. Increased thromboxane biosynthesis is associated with post-stroke dementia. **Stroke**, 30:1542-1547, 1999.
- 125) Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. **Epidemiology**, 11:382-387, 2000.
- 126) Patrignani P, Panara MR, Tacconelli S, Seta F, Bucciarelli T, Ciabattoni G, Alessandrini P, Mezzetti A, Santini G, Sciulli MG, Cipollone F, Davì G, Gallina P, Bittolo Bon G, Patrono C. A

randomized, placebo-controlled dose-finding study of the effect of vitamin E supplementation on F<sub>2</sub>-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. **Circulation**, 102:539-545, 2000.

127) Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Cuccurullo F, Patrono C. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. **Circulation**, 102:1007-1013, 2000

128) Ciabattoni G, Davì G, Collura M, Iapichino L, Pardo F, Ganci A, Romagnoli R, Maclouf J, Patrono C. *In vivo* lipid peroxidation and platelet activation in cystic fibrosis. **Am J Respir Crit Care Med**, 162:1195-1201, 2000.

129) Patrono C, Collier B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G. Platelet-Active Drugs: The relationships among dose, effectiveness, and side effects. **Chest**, 119:39S-63S, 2001.

130) FitzGerald GA, Patrono C. The Coxibs, Selective Inhibitors of Cyclooxygenase-2. **N Engl J Med**, 345:433-442, 2001.

131) Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. **J Clin Invest**, 108:7-13, 2001.

132) Davì G, Di Minno G, Coppola A, Andria G, Cerbone AM, Falco A, Marchesani P, Buccialrelli T, Ciabattoni G, Patrono C. Oxidative stress and platelet activation in homozygous homocystinuria. **Circulation**, 104:1124-1128, 2001.

133) Santini G, Patrignani P, Sciulli MG, Seta F, Tacconelli S, Panara MR, Ricciotti E, Capone M, Patrono C. The human pharmacology of monocyte COX-2 inhibition by cortisol and synthetic glucocorticoids. **Clin Pharmacol Ther**, 70:475-483, 2001.

134) Thun MJ, Henly SJ, Patrono C. Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacological and clinical issues. **J Natl Cancer Inst**, 94:252-262, 2002.

135) Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. **Proc Natl Acad Sci USA**, 99:7634-7639, 2002.

136) Cipollone F, Patrono C. Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury. **Arterioscler Thromb Vasc Biol**, 22:1516-1518, 2002.

137) Davì G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. **JAMA**, 288:2008-2014, 2002.

138) Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R, Seta F, Capone ML, Tacconelli S, Palestri S, Bencini C, Del Vecchio C, Mansueto G, Arosio E, Lechi Santoastaso C, Lechi A, Morganti A, Patrono C. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. **Circulation**, 106:2800-2805, 2002.

- 139) Baigent C, Patrono C. Selective cyclooxygenase-2 inhibitors, aspirin and cardiovascular disease: a re-appraisal. **Arthritis Rheum**, 48:12-20, 2003.
- 140) De Cristofaro R, Rocca B, Vitacolonna E, Falco A, Marchesani P, Ciabattoni G, Landolfi R, Patrono C, Davì G. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. **J Thromb Haemostas**, 1:250-256, 2003.
- 141) Davì G, Chiarelli F, Pomicio MP, Santilli F, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus. Role of interleukin-6 and disease duration. **Circulation**, 107:3199-3203, 2003.
- 142) Patrono C. Aspirin Resistance: Definition, Mechanisms and Clinical Read-Outs. **J Thromb Haemostas**, 1:1710-1713, 2003.
- 143) Minuz P, Patrignani P, Gaino S, Seta F, Capone ML, Tacconelli S, Degan Maurizio, Faccini G, Fornasiero A, Talamini G, Tommasoli R, Arosio E, Lechi Santonastaso C, Lechi A, Patrono C. Determinants of platelet activation in human essential hypertension. **Hypertension**, 43:64-70, 2004.
- 144) Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T. Efficacy and safety of low-dose aspirin in polycythemia vera. **N Engl J Med**, 350:114-124, 2004.
- 145) Patrono C, Bachmann F, Baigent C, Bode C, Charbonnier B, De Caterina R, Fitzgerald D, García Rodríguez LA, Hirsh J, Husted S, Kvasnicka J, Montalescot G, Verheugt F, Vermylen J, Wallentin L. Expert Consensus Document on the Use of Antiplatelet Agents. **Eur Heart J**, 25: 166-81, 2004.
- 146) Davì G, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. **Chemistry and Physics of Lipids**, 128:149-163, 2004.
- 147) Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. **Arterioscler Thromb Vasc Biol**, 24:246-255, 2004.
- 148) Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P. Clinical pharmacology of platelet, monocyte and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. **Circulation**, 109:1468-1471, 2004.
- 149) Patrono C, Collier B, FitzGerald GA, Hirsh J, Roth G. Platelet-Active Drugs: The relationships among dose, effectiveness, and side effects. **Chest**, 126: 234S-264S, 2004.
- 150) Rocca B, Secchiero P, Celeghini C, Ranelletti FO, Ciabattoni G, Maggiano N, Habib A, Ricerca BM, Patrono C, Zauli G. Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. **Experimental Hematology**, 32:925-934, 2004.
- 151) Davì G, Neri M, Festi D, Falco A, Taraborelli T, Ciabattoni G, Cucurullo F, Patrono C. Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. **Arterioscler Thromb Vasc Biol**, 25:246-251, 2005.
- 152) Patrono C, Falco A, Davì G. Isoprostane Formation and Inhibition in Atherothrombosis. **Curr Opin Pharmacol**, 5:198-203, 2005.

- 153) Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. **J Clin Oncol**, 23:2224-2232, 2005.
- 154) Davì G, Falco A, Patrono C. Lipid peroxidation in diabetes mellitus. **Antioxid Redox Signal**, 7:256-268, 2005.
- 155) Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T. Acute leukaemia in polycythemia vera: an analysis of 1,638 patients enrolled in a prospective observational study. **Blood**, 105:2664-2670, 2005.
- 156) Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. **J Thromb Haemost**, 8:1597-1602, 2005.
- 157) Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. **N Engl J Med**, 353: 2373-2383, 2005.
- 158) Born G, Patrono C. Antiplatelet Drugs. **Br J Pharmacol**, 147:S241-S251, 2006.
- 159) Santilli F, Davì G, Consoli A, Cipollone F, Mezzetti A, Falco A, Taraborelli T, Devangelio E, Ciabattoli G, Basili S, Patrono C. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. **J Am Coll Cardiol**, 47:391-397, 2006.
- 160) Ciabattoli G, Porreca E, Di Febbo C, Di Iorio A, Paganelli R, Bucciarelli T, Pescara L, Del Re L, Giusti C, Falco A, San A, Patrono C, Davì G. Determinants of platelet activation in Alzheimer's disease. **Neurobiol Aging**, 28:336-342, 2007.
- 161) Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. **BMJ**, 332:1302-1308, 2006.
- 162) Renda G, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, Zimarino M, Grana M, D'Amelio E, Zurro M, Price TS, Patrono C, De Caterina R, Patrignani P. Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. **Clin Pharmacol Ther**, 80:264-274, 2006.
- 163) Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, Ciabattoli G, Patrono C, Davì G. Insulin resistance as a determinant of platelet activation in obese women. **J Am Coll Cardiol**, 48:2531-2538, 2006.
- 164) Landolfi R, Di Gennaro L, Novarese L, Patrono C. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. **Semin Thromb Hemost**, 32:251-259, 2006.
- 165) Patrono C. The PGH-synthase system and isozyme-selective inhibition. **J Cardiovasc Pharmacol**, 47:Suppl 1;S1-S6, 2006.
- 166) Patrono C, Rocca B. Drug insight: aspirin resistance- fact or fashion? **Nat Clin Pract Cardiovasc Med**, 4:42-50, 2007.



- 167) Davì G, Patrono C. Platelet activation and atherothrombosis. **N Engl J Med**, 357:2482-2494, 2007.
- 168) Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8<sup>th</sup> Edition). **Chest** 133:199S-233S, 2008.
- 169) Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. **Arterioscler Thromb Vasc Biol**, 28:25S-32S, 2008.
- 170) Baigent C, Patrono C. Selective COX-2 inhibitors: where do we go from here? **Lancet**, 372:1712-1713, 2008.
- 171) Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davì G, Patrono C. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. **J Am Coll Cardiol**, 53:667-677, 2009.
- 172) Patrono C. The P2Y12 receptor: no active metabolite, no party. **Nat Rev Cardiol**, 6:271-272, 2009.
- 173) Patrono C, Baigent C. Low-Dose Aspirin, Coxibs, and other NSAIDS: A Clinical Mosaic Emerges. **Mol Interv**, 9:31-39, 2009.
- 174) Patrono C, Rocca B. Nonsteroidal Antiinflammatory Drugs: Past, Present and Future. **Pharmacol Res**, 59:285-289, 2009.
- 175) Patrono C, Rocca B. Aspirin, 110 years later. **J Thromb Haemost**, 7(suppl.1):258-261, 2009.
- 176) ATT Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. **Lancet**, 373:1849-1860, 2009.
- 177) Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G, Mucci L, Ferrante E, Habib A, Ranelletti FO, Ciabattoni G, Davì G, Patrono C, Rocca B. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-insensitive essential thrombocythemia: implications for antiplatelet therapy. **Blood**, 115:1054-1061, 2010.
- 178) Patrono C, Rocca B. The Future of Antiplatelet Therapy in Cardiovascular Disease. **Ann Rev Med**, 61:49-61, 2010.
- 179) Santilli F, Formoso G, Sbraccia P, Averna M, Miccoli R, Di Fulvio P, Ganci A, Pulizzi N, Lattanzio S, Ciabattoni G, Consoli A, Lauro R, Patrono C, Davì G. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. **J Thromb Haemost**, 8:828-837, 2010.
- 180) Davì G, Santilli F, Patrono C. Nutraceuticals in diabetes and metabolic syndrome. **Cardiovasc Therap**, 28:216-226, 2010.
- 181) Santilli F, Davì G, Basili S, Lattanzio S, Cavoni A, Guizzardi G, De Feudis L, Traisci G, Pettinella C, Minuz P, Meneguzzi A, Ciabattoni G, Patrono C. Thromboxane and Prostacyclin

Biosynthesis in Heart Failure of Ischemic Origin: Effects of Disease Severity and Aspirin Treatment. **J Thromb Haemost**, 8:914-922, 2010.

182) Patrono C, Baigent C. Aspirin for Asymptomatic Atherosclerosis? **Nature Rev Cardiol**, 7:306-307, 2010.

183) Petrucci G, De Cristofaro R, Rutella S, Ranelletti FO, Pocaterra D, Lancellotti S, Habib A, Patrono C, Rocca B. Prostaglandin E<sub>2</sub> differentially modulates human platelet function through the EP<sub>2</sub> and EP<sub>3</sub> receptors. **J Pharmacol Exp Ther**, 336:391-402, 2011.

184) Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet J-P, De Caterina R, Gulba D, Huber K, Husted S, Kristensen SD, Morais J, Neumann F-J, Rasmussen LH, Siegbahn A, Steg P-G, Storey RF, Van de Werf F, Verheugt F. Antiplatelet agents for the treatment and prevention of atherothrombosis. **Eur Heart J**, 32:2922-2932, 2011.

185) Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, Patrono C. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. **Blood**, 119:3595-3603, 2012.

186) Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. **Nat Rev Clin Oncol**, 9:259-267, 2012.

187) Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, Lattanzio S, Mattoscio D, Zaccardi F, Liani R, Vazzana N, Del Ponte A, Ferrante E, Martini F, Ghirlanda G, Davì G, Patrono C. The Recovery of Platelet Cyclooxygenase Activity Explains Interindividual Variability in Responsiveness to Low-Dose Aspirin in Patients With and Without Diabetes. **J Thromb Haemost**, 10:1220-1230, 2012.

188) Grassi MC, Chiamulera C, Baraldo M, Culasso F, Ferketich AK, Raupach T, Patrono C, Nencini P. Cigarette smoking knowledge and perceptions among students in four Italian medical schools. **Nicotine & Tobacco Res**, 14:1065-1072, 2012.

189) Patrono C. Diabetes: Does aspirin increase the risk of major bleeds? **Nat Rev Cardiol**, 9:495-496, 2012.

190) Dragani A, Falco A, Santilli F, Basili S, Ronaldi G, Cerasa L, Lattanzio S, Ciabattini G, Patrono C, Davì G. Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinemia due to MTHFR 677 C-T polymorphism. **Thromb Haemost**, 108:533-542, 2012.

191) Patrono C. Aspirin Continues to Attract Research and Debate, 115 Years After Its Synthesis. **Rev Espan Cardiol**, 66:251-254, 2013.

192) Patrono C. Low-Dose Aspirin in Primary Prevention: Cardioprotection, Chemoprevention, Both or Neither? **Eur Heart J**, 34:2403-2411, 2013.

193) Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. **Blood**, 121:1701-1711, 2013.

- 194) Patrono C, Andreotti F. Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety. **Circulation**, 128:684-686, 2013.
- 195) Rydén L, Grant PJ, Anker SD, Berne C, Consentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marra M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Sousa Uva M, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. **Eur Heart J**, 34:3035-3087, 2013.
- 196) Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. **Lancet**, 382:769-779, 2013.
- 197) Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. **Circulation**, 129:907-916, 2014.
- 198) Grassi MC, Baraldo M, Chiamulera C, Culasso F, Raupach T, Ferketich AK, Patrono C, Nencini P. Knowledge about health effects of cigarette smoking and quitting among italian university students: the importance of teaching nicotine dependence and treatment in the medical curriculum. **Biomed Res Int**, 2014;2014:321657.
- 199) Cavalca V, Rocca B, Squellerio I, Dragani A, Veglia F, Pagliaccia F, Porro B, Barbieri SS, Tremoli E, Patrono C. In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythemia. **Thrombosis and Haemostasis**, 112: 118-127, 2014.
- 200) Patrignani P, Tacconelli S, Piazuolo E, Di Francesco L, Dovizio M, Sostres C, Marcantoni E, Guillem-Llobat P, Del Boccio P, Zucchelli M, Patrono C, Lanas A. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. **J Thromb Haemost**, 12:1320-1330, 2014.
- 201) Patrono C. Role of clinical pharmacology in the development of antiplatelet drugs. **Clin Ther** 36: 2096-111, 2014.
- 202) Patrignani P, Patrono C. Cyclooxygenase inhibitors: from pharmacology to clinical read-outs. **Biochim Biophys Acta**, 1851:422-432, 2015.
- 203) Patrono C. The multifaceted clinical read-outs of platelet inhibition by low-dose aspirin. **J Am Coll Cardiol**, 66:74-85, 2015.
- 204) Andreotti F, Rocca B, Husted S, Ajjan RA, ten Berg J, Cattaneo M, Collet J-P, De Caterina R, Fox KAA, Halvorsen S, Huber K, Hylek EM, Lip GYH, Montalescot G, Morais J, Patrono C, Verheugt FWA, Wallentin L, Weiss TW, Storey RF, on behalf of the ESC Thrombosis Working Group. Antithrombotic Therapy in the Elderly: Expert Position Paper of the ESC Working Group on Thrombosis. **Eur Heart J**, 36:3238-3249, 2015.
- 205) Rocca B, Patrono C. Platelet progenitors: the hidden drug target. **Eur Heart J**, 36:3211-3213, 2015.

- 206) Santilli F, Davì G, Patrono C. Homocysteine, ethylenetetrahydrofolate reductase, folate status and atherothrombosis: a mechanistic and clinical perspective. **Vascular Pharmacol**, 78:1-9, 2016.
- 207) Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). **Eur Heart J**, 37:267-315, 2016.
- 208) Zaccardi F, Rizzi A, Petrucci G, Ciaffardini F, Tanese L, Pagliaccia F, Cavalca V, Ciminello A, Habib A, Squellerio I, Rizzo P, Tremoli E, Rocca B, Pitocco D, Patrono C. In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes. **Diabetes**, 65:503-509, 2016.
- 209) Patrono C. Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs. **Curr Cardiol Rep**, Mar;18:25, 2016.
- 210) Roffi M, Gencer B, Storey RF, Andreotti F, Patrono C. Clinical Perspectives and Pearls from the 2015 ESC NSTEMI-ACS Guidelines. **Curr Cardiol Rep**, May;18:48, 2016.
- 211) Guillem-Llobat, P, Dovizio M, Bruno A, Ricciotti E, Cufino V, Sacco A, Grande R, Alberti S, Arena V, Cirillo M, Patrono C, FitzGerald GA, Steinhilber D, Sgambato A, Patrignani P. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. **Oncotarget**, 7:32462-32477, 2016.
- 212) Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. **Br J Clin Pharmacol**, 82:957-964, 2016.
- 213) Petrucci G, Rizzi A, Cavalca V, Habib A, Pitocco D, Veglia F, Ranalli P, Zaccardi F, Pagliaccia F, Tremoli E, Patrono C, Rocca B. Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement. **Thromb Haemost**, 116:891-896, 2016.
- 214) Patrignani P, Patrono C. Aspirin and Cancer. **J Am Coll Cardiol**, 68:967-976, 2016.
- 215) Mueller C, Patrono C, Roffi M. Should the 1h algorithm for rule in and rule out of acute myocardial infarction be used universally? **Eur Heart J**, 37:3316-3323, 2016.
- 216) Patrono C, Rocca B. Type 2 diabetes, obesity and aspirin responsiveness. **J Am Coll Cardiol**, 69:613-615, 2017.
- 217) Cavalca V, Rocca B, Veglia F, Petrucci G, Porro B, Myasoedova V, MD, De Cristofaro R, Turnu L, Bonomi A, Songia P, Cavallotti L, Zanobini M, Camera M, Alamanni F, Parolari A, Patrono C, Tremoli E. On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens. **Clin Pharmacol Ther**, 102:849-858, 2017.
- 218) Patrignani P, Sacco A, Sostres C, Bruno A, Dovizio M, Piazuolo E, Di Francesco L, Contursi A, Zucchelli M, Schiavone S, Tacconelli S, Patrono C, Lanas A. Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. **Clin Pharmacol Ther**, 102:52-61, 2017.

- 219) Giaretta A, Rocca B, Di Camillo B, Toffolo GM, Patrono C. In silico modeling of the antiplatelet pharmacodynamics of low-dose aspirin in health and disease. **Clin Pharmacol Ther**, 102:823-831, 2017.
- 220) Patrono C, Baigent C. Coxibs, NSAIDs and cardiovascular safety post PRECISION: what we thought we knew then and what we think we know now. **Clin Pharmacol Ther**, 102:238-245, 2017.
- 221) Gaudino M, Benedetto U, Antoniadis C, Di Franco A, Fremez S, Glineur D, Grau J, He G-W, Ohmes LB, Patrono C, Puskas J, Tranbaugh R, Girardi LN, Taggart D. Mechanisms, consequences, and prevention of coronary graft failure. **Circulation**, 136:1749-1764, 2017.
- 222) Patrono C, Morais J, Baigent C, Collet J-P, Fitzgerald D, Halvorsen S, Rocca B, Siegbahn A, Storey RF, Vilahur G. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. **J Am Coll Cardiol**, 70:1760–1776, 2017.
- 223) Patrono C. Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context. **Cardiovasc Res**, 113:e61-e63, 2017.
- 224) Rocca B, Fox KAA, Ajjan RA, Andreotti F, Baigent C, Collet J-P, Grove EL, Halvorsen S, Huber K, Morais J, Patrono C, Rubboli A, Seljeflot I, Sibbing D, Siegbahn A, Ten Berg J, Vilahur G, Verheugt FWA, Wallentin L, Weiss TW, Wojta J, Storey RF. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. **Eur Heart J**, 39:1672-1686f,2018.
- 225) Patrignani P, Patrono C. Aspirin, platelet inhibition and cancer prevention. **Platelets** 29:779-785, 2018.
- 226) Scally B, Emberson J, Spata E, Reith C, Davies K, Halls H, Holland L, Wilson K, Bhala N, Hawkey C, Hochberg M, Hunt R, Laine L, Lanasa A, Patrono C, Baigent C. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. **Lancet Gastroenterol Hepatol**, 3:231-241, 2018.
- 227) De Stefano V, Rocca B, Tosetto A, Soldati D, Petrucci G, Beggiato E, Bertozzi I, Betti S, Carli G, Carpenedo M, Cattaneo D, Cavalca V, Dragani A, Elli E, Finazzi G, Iurlo A, Lanzarone G, Lissandrini L, Palandri F, Paoli C, Rambaldi A, Ranalli P, Randi ML, Ricco A, Rossi E, Ruggeri M, Specchia G, Timillero A, Turnu L, Vianelli N, Vannucchi AM, Rodeghiero F, Patrono C. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design - implementation of the serum thromboxane B2 assay as an evaluation tool of different dosing regimens in the clinical setting. **Blood Cancer J** 2018;8:49 DOI 10.1038/s41408-018-0078-3.
- 228) Gaudino M, Angelini GD, Antoniadis C, Bakaeen F, Benedetto U, Calafiore AM, Di Franco A, Di Mauro M, Fremez SE, Girardi LN, Glineur D, Grau J, He G-W, Patrono C, Puskas JD, Ruel M, Schwann TA, Tam DY, Tatoulis J, Tranbaugh R, Valley M, Zenati MA, Mack M and Taggart DP. Off-pump coronary artery bypass grafting: 30 years of debate. **J Am Heart Ass** 7:e009934, 2018.
- 229) Sacco A, Bruno A, Contursi A, Dovizio M, Tacconelli S, Ricciotti E, Guillem-Llobat P, Salvatore T, Di Francesco L, Ballerini P, Arena V, Alberti S, Liu G, Gong Y, Sgambato A, Akira S, Patrono C, FitzGerald GA, Yu Y, and Patrignani P. Platelet-specific deletion of cyclooxygenase-1

ameliorates dextran sulfate sodium-induced colitis in mice. **J Pharmacol Exp Ther** 370:416-426, 2019.

230) Patrono C, Baigent C. Aspirin therapy for primary cardiovascular disease prevention. **Nature Rev Cardiol** 16:675-686, 2019.

231) Santilli F, Zaccardi F, Liani R, Petrucci G, Simeone P, Pitocco D, Tripaldi R, Rizzi A, Formoso G, Pontecorvi A, Angelucci E, Pagliaccia F, Golato M, De Leva F, Vitacolonna E, Rocca B, Consoli A, and Patrono C. In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance. **Diabetes Metab Res Rev** 2020 Feb;36(2):e3232.

232) Patrono C, Rocca B. Measurement of thromboxane biosynthesis in health and disease. **Front Pharmacol** 2019 Oct 30;10:1244.

233) Rocca B, Tosetto A, Betti S, Soldati D, Petrucci G, Rossi E, Timillero A, Cavalca V, Porro B, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli N, Beggiano E, Lanzarone G, Ruggeri M, Carli G, Elli E, Carpenedo M, Bertozzi I, Paoli C, Randi ML, Ricco A, Specchia G, Vannucchi AM, Rodeghiero F, Patrono C, De Stefano V. A randomized, double blind trial of three low-dose aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. **Blood** 136:171-182, 2020.

234) Rocca B, Patrono C. Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. **Diabetes Res Clin Pract** 2020 Feb;160:108008.

235) Drew DA, Schuck MM, Magicheva-Gupta M, Stewart KO, Gilpin KK, Miller P, Parziale MP, Pond E, Takacs-Nagy O, Zerjav DC, Chin SM, Mackinnon Krems J, Meixell D, Joshi AD, Ma W, Collizzo III FP, Carolan P, Nishioka NS, Staller K, Richter JM, Hamed Khalili H, Gala M, Garber JJ, Chung DC, Yarze JC, Zukerberg L, Petrucci G, Rocca B, Patrono C, Milne G, Wang M, Chan AT. Aspirin reduces PGE<sub>2</sub>-biosynthesis to levels associated with reduced risk of colorectal adenoma and cancer: the ASPIRED randomized trial primary outcome. **Cancer Prev Res (Phila)** 13:877-888,2020.

236) Andreotti F, Geisler T, Collet J-P, Gigante B, Halvorsen S, Lip GYH, Morais J, Navarese EP, Patrono C, Rocca B, Sibbing D, Storey RF, Verheugt FWA, Vilahur G, Gorog DA, Rubboli A. Acute, periprocedural and long-term antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis. **Eur Heart J** (in press).

237) Tosetto A, Rocca B, Petrucci G, Betti S, Soldati D, Rossi E, Timillero A, Cavalca V, Porro B, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli N, Beggiano E, Lanzarone G, Ruggeri M, Carli G, Elli EM, Priolo S, Randi ML, Bertozzi I, Loscocco G, Ricco A, Specchia G, Vannucchi AM, Rodeghiero F, De Stefano V, Patrono C. Association of platelet thromboxane inhibition by low-dose aspirin with platelet count and cytoreductive therapy in essential thrombocythemia. **Clin Pharmacol Ther** 111:939-949;2022.

238) Badimon L, Vilahur G, Rocca B, Patrono C. The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. **Cardiovasc Res** 117:2001-2015;2021.

- 239) Rocca B, Patrono C. Aspirin at 120: Retiring, Recombining, or Repurposing? **Res Pract Thromb Haemost.** 2021;5:e12516.
- 240) Petrucci G, Giaretta A, Ranalli P, Cavalca V, Dragani A, Porro B, Hatem D, Habib A, Tremoli E, Patrono C, Rocca B. Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: *ex vivo* and *in vivo* measurements and *in silico* simulation. **Clin Transl Science** 2022;00:1-13.
- 241) Patrono C, Rocca B. Less Thromboxane, Longer Life. **J Am Coll Cardiol** 80:251-255;2022.
- 242) Mantovani A, Morrone MC, Patrono C, Santoro MG, Schiaffino S, Remuzzi G, and Bussolati G. Long COVID: where we stand and challenges ahead. **Cell Death Differ** 29:1891-1900.2022.
- 243) Patrono C. Fifty years with aspirin and platelets. **Br J Pharmacol** 2022; 1-19.
- 244) Remuzzi G, Schiaffino S, Santoro MG, FitzGerald GA, Melino G, Patrono C. Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. **Front Pharmacol** 2022;13:987816.

## SHORT COMMENTARIES (European Heart Journal, Weekly Journal Scan)

1. Liuzzo G, Patrono C. Low-dose colchicine: a new tool in the treatment of chronic coronary disease? Comment on the low-dose colchicine (LoDoCo)2 trial. **Eur Heart J.** 2020; 41:3880-3881.
2. Liuzzo G, Patrono C. EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial. **Eur Heart J.** 2020; 41:3881-3882
3. Liuzzo G, Patrono C. Low-dose edoxaban for stroke prevention in elderly patients with atrial fibrillation: Comment on the edoxaban low-dose for elder care atrial fibrillation patients (ELDERCARE-AF) Trial. **Eur Heart J.** 2020; 41:3882-3883.
4. Galiuto L, Patrono C. Early rhythm control for early atrial fibrillation? Comment on the EAST-AFNET 4 Trial. **Eur Heart J.** 2020; 41:3987-3988.
5. Volpe M, Patrono C. Out-of-hospital cardiac arrest: handle with care. Comment on the Resuscitation Outcomes Consortium Cardiac Epidemiologic Registry. **Eur Heart J.** 2020; 41:4165-4166.
6. Patrono C, Galiuto L. Weak hypothesis? Wrong pharmacologic tool? Inadequate experimental design? Comment on the ATPCI trial. **Eur Heart J.** 2020; 41:4166-4167.
7. Galiuto L, Patrono C. New hope for targeted treatment of obstructive hypertrophic cardiomyopathy: comment on the EXPLORER-HCM trial. **Eur Heart J.** 2020; 41:4089-4090
8. Liuzzo G, Patrono C. Management of chronic kidney disease and its cardiovascular complications: has the dawn of a new era arrived? Comment on Dapagliflozin in Patients with Chronic Kidney Disease. **Eur Heart J.** 2020; 41:4231-4232
9. Volpe M, Patrono C. Do VERTIS-CV trial results question a class-effect of cardiovascular protection with sodium-glucose cotransporter 2 inhibitors? **Eur Heart J.** 2020; 41:4232-4233.
10. Galiuto L, Patrono C. Aspirin Monotherapy vs. DAPT after TAVI: Is Less More? Comment on the POPular TAVI Trial. **Eur Heart J.** 2020; 41:4301-4302.
11. Galiuto L, Patrono C. Conflicting results on the efficacy of remdesivir in hospitalized Covid-19 patients: comment on the Adaptive Covid-19 Treatment Trial. **Eur Heart J.** 2020; 41:4387-4388.
12. Liuzzo G, Patrono C. The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the 'Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19. **Eur Heart J.** 2020; 41:4389-4390
13. Volpe M, Patrono C. The second life of the ambiguous angiotensin-converting enzyme 2 as a predictive biomarker for cardiometabolic diseases and death. **Eur Heart J.** 2020; 41:4302-4303.
14. Volpe M, Patrono C. Decline in blood pressure control trends in the US: a real step back: Comment on National Health and Nutrition Examination Survey (NHANES) data. **Eur Heart J.** 2020; 41:3986-3987.
15. Liuzzo G, Patrono C. COVID 19: in the eye of the cytokine storm. **Eur Heart J.** 2021; 42:150-151.
16. Galiuto L, Patrono C. Preventing a diabetes pandemic through lifestyle intervention. **Eur Heart J.** 2021; 42:226-227.
17. Patrono C. The EHJ Weekly Journal Scan: Why? Who? How? **Eur Heart J.** 2021; 42:224-226.



18. Volpe M, Patrono C. The REDUCE-IT verdict on eicosapentaenoic acid and cardiovascular outcome challenged with STRENGTH. **Eur Heart J.** 2021; 42:370-371.
19. Galiuto L, Patrono C. Physical activity and mortality reduction: is volume or intensity the key variable? **Eur Heart J.** 2021; 42:730-731.
20. Volpe M, Patrono C. Iron heart. **Eur Heart J.** 2021; 42:809-810.
21. Liuzzo G, Patrono C. Occluding to prevent occlusion. **Eur Heart J.** 2021; 42:3224-3225.
22. Liuzzo G, Patrono C. A one-size-fits-all polypill strategy for primary prevention in the era of precision medicine? **Eur Heart J.** 2021; 42:561-562.
23. Liuzzo G, Patrono C. Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians. **Eur Heart J.** 2021; 42:882-883.
24. Galiuto L, Patrono C. Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve. **Eur Heart J.** 2021; 42:811-812.
25. Liuzzo G, Patrono C. StatinWISE sheds new light on statin-related muscle symptoms. **Eur Heart J.** 2021; 42:1726-1727.
26. Patrono C, Volpe M. Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems. **Eur Heart J.** 2021; 42:14-15.
27. Volpe M, Patrono C. Vulnerable non-culprit coronary plaques: are they worth treating? **Eur Heart J.** 2021; 42:2233-2234.
28. Galiuto L, Patrono C. Challenging the Role of Aspirin for Long-Term Antiplatelet Therapy? **Eur Heart J.** 2021; 42:2883-2884.
29. Volpe M, Patrono C. A SPRINT towards tighter control of blood pressure in hypertension. **Eur Heart J.** 2021; 42:3042-3043.
30. Liuzzo G, Patrono C. Aspirin-free antiplatelet strategies: is the evidence supporting a paradigm shift? **Eur Heart J.** 2021; 42:4011-4012.
31. Volpe M, Patrono C. Another STEP towards tighter control of blood pressure in the elderly. **Eur Heart J.** 2021; 42:4715-4716.
32. Liuzzo G, Patrono C. Interleukin-1 blockade: a paradigm shift in the treatment of patients with recurrent pericarditis? **Eur Heart J.** 2021; 42:1287-1288.
33. Liuzzo G, Patrono C. First in man: gene editing for the treatment of transthyretin amyloidosis. **Eur Heart J.** 2021; 42:3597-3598.
34. Liuzzo G, Patrono C. Are US cardiologists ADAPTABLE to considering low-dose aspirin for secondary prevention? **Eur Heart J.** 2021; 42:2525-2526.
35. Patrono C, Volpe M. PCSK9 inhibition: Not just LDL-Cholesterol knock down: A glimmer for cancer. **Eur Heart J.** 2021; 42:1130-1131.
36. Volpe M, Patrono C. Worsening of risk factor control in US diabetic patients: a call to action. **Eur Heart J.** 2021; 42:3120-3121.
37. Liuzzo G, Patrono C. When less is more: dual antiplatelet therapy in elective percutaneous coronary intervention. **Eur Heart J.** 2021; 42:965-966.
38. Paneni F, Patrono C. Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes? **Eur Heart J.** 2021; 42:4211-4212.
39. Narducci ML, Patrono C. Abelacimab and factor XI inhibition: a novel mechanism for the prevention of venous thromboembolism. **Eur Heart J.** 2021; 42:4109-4110.
40. Volpe M, Patrono C. The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. **Eur Heart J.** 2021; 42:1458-1459.
41. Volpe M, Patrono C. A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19. **Eur Heart J.** 2021; 42:1061-1062.
42. Volpe M, Patrono C. A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetes. **Eur Heart J.** 2021; 42:3902-3903.

43. Volpe M, Patrono C. The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis. **Eur Heart J.** 2021; 42:4518-4519.
44. Volpe M, Patrono C. The key role of blood pressure lowering in cardiovascular prevention irrespective of baseline blood pressure and risk profile. **Eur Heart J.** 2021; 42:2814-2815.
45. Liuzzo G, Patrono C. Does abbreviated dual antiplatelet therapy after PCI provide a clinically meaningful trade-off between bleeding and ischaemic events in patients at high risk for bleeding? **Eur Heart J.** 2021; 42:4418-4419.
46. Volpe M, Patrono C. The increased mortality of STEMI patients without risk factors supports the need for evidence-based pharmacotherapy irrespective of perceived low risk. **Eur Heart J.** 2021; 42:2329-2330.
47. Volpe M, Patrono C. The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction. **Eur Heart J.** 2021; 42:4621-4623.
48. Volpe M, Patrono C. Blood pressure lowering drugs differ in their capacity to prevent type 2 diabetes. **Eur Heart J** 2022;43:1189-1190.
49. Liuzzo G, Patrono C. Can targeting factor XIa dissociate thrombosis from haemostasis? **Eur Heart J** 2022;43:1031-1032.
50. Liuzzo G, Patrono C. Give genotype-guided dual antiplatelet therapy a second CHANCE. **Eur Heart J** 2022;43:938-939.
51. Liuzzo G, Patrono C. *In vivo* generated CAR T-cells reduce fibrosis and restore cardiac function in experimental heart failure. **Eur Heart J** 2022; 43:1531-1532.
52. Paneni F, Patrono C. Increased risk of incident diabetes in patients with long COVID. **Eur Heart J** 2022;43:2094-2095.
53. Vergallo R, Patrono C. The PACMAN-AMI trial: game over for the “vulnerable plaque”? **Eur Heart J** 2022;43:2179-2180.
54. Liuzzo G, Patrono C. Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonism for substantial body weight reduction in obese subjects. **Eur Heart J** 2022; 43:3288-3289.
55. Volpe M, Patrono C. One-shot thrombolysis for the management of acute ischaemic stroke. **Eur Heart J** 2022; 43:3616-3617.
56. Liuzzo G, Patrono. Long-term use of proton pump inhibitors and risk of diabetes mellitus: the totality of the evidence does not support a change in practice. **Eur Heart J** 2022; 43: 3995–3996.
57. Galiuto L, Patrono C. Efficacy of a mediterranean diet for the secondary prevention of cardiovascular disease. **Eur Heart J** 2022;43:2727-2728.
58. Galiuto L, Patrono C. Differential cardiovascular effects of disease-modifying antirheumatic drugs in rheumatoid arthritis. **Eur Heart J** 2022;43:1615-1616.
59. Liuzzo G, Patrono C. The absolute cardiovascular benefits of PCSK9 inhibitors and ezetimibe added to maximally tolerated statin therapy depend on individual baseline cardiovascular risk. **Eur Heart J** 2022;43:3016–3017.
60. Volpe M, Patrono C. Age-independent benefits of blood pressure lowering: are they applicable to all patients? **Eur Heart J** 2022;43:448-449.
61. Volpe M, Patrono C. Drugs may worsen blood pressure control: focus on the underestimated role of non-steroidal anti-inflammatory drugs. **Eur Heart J** 2022;43:1377-1378.
62. Liuzzo G, Patrono C. Placing the risk of myopericarditis following COVID-19 vaccination into perspective. **Eur Heart J** 2022;43:2547-2548.
63. Liuzzo G, Patrono C. Can low-dose aspirin help the RECOVERY of patients hospitalized with COVID-19? **Eur Heart J** 2022;43:714-715.
64. Liuzzo G, Patrono C. A novel inhibitor of Factor XIa as potential haemostasis-sparing anticoagulant for patients with atrial fibrillation. **Eur Heart J** 2022;43:2354-2355.

65. Liuzzo G, Patrono C. Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital. **Eur Heart J** 2022;43:365-366.
66. Liuzzo G, Patrono C. Solid evidence that very few muscle symptoms are due to statin therapy. **Eur Heart J** 2022;
67. Vergallo R, Patrono C. Antiplatelet therapy to prevent graft failure after coronary artery bypass graft: aspirin monotherapy for most, DAPT for selected few. **Eur Heart J** 2022;43:4456-4457.
68. Liuzzo G, Patrono C. A SECURE polypill as a strategy at the heart of secondary prevention. **Eur Heart J** 2022; 43:4534-4535.
69. Liuzzo G, Patrono C. Vitamin K Antagonists Remain the INVICTUS Standard of Care for Patients with Rheumatic Heart Disease and Atrial Fibrillation. **Eur Heart J** 2022;
70. Volpe M, Patrono C. The promise of selective aldosterone synthase inhibition for the management of resistant hypertension. **Eur Heart J** Dec 20:ehac754.
71. Liuzzo G, Patrono C. *Helicobacter Pylori* Eradication as a Gastroprotective Strategy in Elderly Aspirin-Treated Subjects: Established Facts and Unanswered Questions. **Eur Heart J** 2023;
72. Liuzzo G, Patrono C. Allopurinol does not improve cardiovascular outcomes in ischaemic heart disease. **Eur Heart J** 2023;

## RECENT INVITED PRESENTATIONS

1. *China Heart Foundation Lecture Tour*, Beijing, Hefei, Shanghai, Wuhan (China), 19-23 April 2017.
2. *L. Jackson Roberts, II, MD Celebration and Symposium*, Vanderbilt University, Nashville (USA), 4 May 2017.
3. *ESM-EVBO Meeting*, Geneva (Switzerland), 31 May 2017.
4. *European Society of Cardiology (ESC) Congress*, Barcelona (Spain), 29 August 2017.
5. *ESC 2017 Highlights*, Charité Universitaetsmedizin, Berlin (Germany), 2 September 2017.
6. *Symposium on "Cardiometabolic Risk and Vascular Disease: from Mechanisms to Treatment"*, Karolinska Institutet, Stockholm (Sweden), 2 December 2017.
7. *American College of Cardiology "New York Cardiovascular Symposium"*, New York (USA), 8 December 2017.
8. *Platelets 2018, 10th International Symposium*, Ramat Gan (Israel), 21-25 April 2018.
9. *International Congress on "Open Issues in Thrombosis and Hemostasis 2018"*, St. Petersburg (Russia), 4-6 October 2018.
10. *International Meeting on "Resolution of Inflammation: mechanisms, mediators and biomarkers"*, Pescara (Italy), 13-16 November 2018.
11. *European Society of Cardiology Congress*, Paris (France), 3 September 2019.
12. *International Antonio Feltrinelli Conference "Ageing: from Basic Science to Policy Advice"*, Rome (Italy), 4-6 November 2019.
13. *XXVIII Congress of the International Society on Thrombosis and Haemostasis (ISTH 2020) Virtual Congress*, July 12-14, 2020.
14. *Oriental Congress of Cardiology*, Shanghai (China), 28 May 2021.
15. *89<sup>th</sup> Congress of the European Atherosclerosis Society*, Helsinki (Finland), 31 May 2021.
16. *International symposium on "Cardiometabolic Risk and Vascular Disease: from Mechanisms to Treatment"*, Karolinska Institutet, Stockholm (Sweden), 20-21 September, 2021.
17. *British Pharmacological Society 90<sup>th</sup> Anniversary Meeting*, London (UK), 1 December 2021.
18. *European Course in Antithrombotic Management*, Maastricht (The Netherlands), 20-24 April 2022.
19. *90<sup>th</sup> Congress of the European Atherosclerosis Society*, Milan (Italy), 23 May 2022.

20. *2022 International Aspirin Foundation Conference*, Berlin, 29<sup>th</sup> September 2022.

21. *EuroThrombosis & EuroVessels 2022*, Lisbon (Portugal), 20-22 October 2022.

22. *European Course in Antithrombotic Management*, Maastricht (The Netherlands), 3-6 November 2022.